We're making updates and relaunching soon. Get notified

Straight answers about GLP-1 medications

Plain-language guides on dosing, side effects, costs, and what to look for in a provider.

Relaunching Soon

  • Relaunching as an independent GLP-1 guide
  • Get notified when we relaunch
  • We only ask for your email
Get Started

One email to confirm. Unsubscribe anytime.

Alcohol on GLP-1: How Semaglutide Affects Drinking Behavior

Many people on GLP-1 medications notice their alcohol tolerance changes. Some report drinking less even when they don’t intend to. Others find that alcohol feels different and less predictable. Here is what researchers know so far and what it may mean for you.

How GLP-1 changes alcohol absorption

GLP-1 medications like semaglutide and tirzepatide slow gastric emptying, which means they delay how quickly food and liquids move from your stomach into your small intestine. Alcohol is absorbed mostly from the small intestine, so slower emptying may change how quickly alcohol reaches your bloodstream.

How that plays out for any one person is not well studied. In one small 2025 trial, people taking low-dose semaglutide reached lower peak breath alcohol levels during a lab drinking session than people on placebo, but they also drank less, so the two effects are hard to separate[2]. What many people describe is simpler: alcohol feels different from what they are used to. Some feel it more, some less, and some feel it later than expected. Because the effect is hard to predict, it makes sense to go slowly until you know how your body responds.

The brain chemistry piece: GLP-1 and reward

There is another mechanism at work. GLP-1 receptors are not just in your digestive system. They are also expressed in the brain’s reward circuits[1]. The same signaling pathways that reduce food noise appear to affect alcohol reward signaling as well.

Animal studies show that GLP-1 receptor agonists reduce alcohol intake and the motivation to drink, and early human studies point in the same direction[3]. Researchers are now testing this in randomized trials. In a phase 2 trial published in JAMA Psychiatry in 2025, 48 adults with alcohol use disorder received low-dose semaglutide or placebo for 9 weeks. Semaglutide reduced the amount of alcohol consumed in a lab drinking session, drinks per drinking day, and weekly alcohol craving. It did not change the average number of drinks per day or the number of drinking days. The authors called the results initial evidence that justifies larger trials[2].

Many people describe something similar in everyday life: they find themselves drinking less alcohol not because they decided to, but because the desire decreased. They go out, have one drink, and do not want another. That does not appear to be willpower. It appears to be the medication changing how rewarding alcohol feels.

This is an emerging area of research. If you are noticing a reduction in how much alcohol appeals to you, that is a recognized effect, and it is worth mentioning to your provider.

Practical considerations for drinking on GLP-1

Even without a listed contraindication, there are real interactions worth understanding.

Low blood sugar. Alcohol can lower blood sugar, especially when you drink without eating, and GLP-1 medications often mean you are eating less. The prescribing information for semaglutide and tirzepatide says these medications lower blood glucose and can cause hypoglycemia, and that the risk is higher when they are used with insulin or an insulin secretagogue such as a sulfonylurea[4][5]. If you take insulin or a sulfonylurea, ask your prescriber how alcohol fits in before you drink, and learn the signs of low blood sugar (shakiness, sweating, confusion, fast heartbeat).

Nausea amplification. Nausea is the most common side effect of GLP-1 medications, especially in the first weeks and after dose increases. Alcohol often worsens nausea. If you are already experiencing nausea from the medication, adding alcohol is likely to make it worse. Some people describe the combination as unpleasant enough that they stop drinking on those days.

Dehydration. Both labels warn about acute kidney injury, mostly reported in people who became dehydrated from nausea, vomiting, or diarrhea[4][5]. Drinking alcohol on top of GI side effects can add to fluid loss. If you drink, have water alongside it, and skip alcohol when you are vomiting or have diarrhea.

Pancreatitis. The labels for both medications warn about acute pancreatitis. Signs include persistent, severe abdominal pain, sometimes spreading to the back, with or without vomiting[4][5]. If you drink heavily or have had pancreatitis before, tell your prescriber. If you develop that kind of pain, seek medical care right away.

The worst timing. Many people find their stomach side effects are strongest in the day or two after their weekly dose and after a dose increase. That is a poor time to drink. If you drink regularly, spacing it away from those days is the more cautious approach.

Tolerance surprise. Some people find they cannot tolerate alcohol the way they used to. A drink or two that used to be fine now causes nausea, flushing, or other side effects. This is not a sign to push through it. It is a sign to adjust.

Is alcohol forbidden on GLP-1?

No. The FDA prescribing information for semaglutide and tirzepatide weight-loss medications does not list alcohol as a contraindication[4][5]. But there are real interactions worth understanding. The practical answer is moderation, awareness of your changed tolerance, and not drinking when you are already nauseous from your dose. Your prescriber can tell you whether your other medications or health conditions change that.

Some people find that their relationship with alcohol simply changes. They drink less because they want to less. Others find they can still drink but need to be more careful about timing, food in their stomach, and paying attention to how their body responds. Both experiences are common.

For patients with a history of alcohol use disorder

Research on GLP-1 medications and alcohol use disorder is active, but it is early. No GLP-1 medication is FDA-approved to treat alcohol use disorder. The 2025 semaglutide trial described above was small and short, and its authors called for larger trials[2]. A 2024 systematic review found mixed results: the largest randomized trial it included (of exenatide, an older GLP-1 medication) did not reduce heavy drinking days overall, while observational studies linked GLP-1 medication use with fewer alcohol-related health events[6].

If you have a history of alcohol misuse and notice a significant change in your relationship with alcohol since starting a GLP-1 medication, discuss it with your provider. Do not stop or change any treatment for alcohol use disorder on your own. This is a promising area of research, and your experience is worth sharing with the people treating you.

What a proper weight loss program should include

Many telehealth programs that prescribe GLP-1 medications include some nutrition or lifestyle guidance, and some include coaching. Others offer only the prescription and occasional check-ins. When you compare programs, check whether you can reach a licensed provider with follow-up questions between visits, including questions about alcohol, other medications, and side effects.

Whatever program you choose, bring these questions to your prescriber. A licensed provider at the program you choose decides whether a prescription is appropriate and can give advice that fits your health history.

Citations

[1] Klausen MK, Thomsen M, Wortwein G, Fink-Jensen A. “The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.” British Journal of Pharmacology. 2022;179(4):625-641. https://pubmed.ncbi.nlm.nih.gov/34532853/

[2] Hendershot CS, Bremmer MP, Paladino MB, et al. “Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.” JAMA Psychiatry. 2025;82(4):395-405. Phase 2 trial, 48 non-treatment-seeking adults with alcohol use disorder, 9 weeks of low-dose semaglutide or placebo. https://pubmed.ncbi.nlm.nih.gov/39937469/

[3] Jerlhag E. “GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.” Endocrinology. 2025;166(4):bqaf028. Review of preclinical and human evidence. https://pubmed.ncbi.nlm.nih.gov/39980336/

[4] Novo Nordisk. WEGOVY (semaglutide) prescribing information, sections 5.2 (acute pancreatitis), 5.4 (hypoglycemia), and 5.5 (acute kidney injury due to volume depletion). Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[5] Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information, sections 5.3 (acute kidney injury due to volume depletion), 5.5 (acute pancreatitis), and 5.7 (hypoglycemia). Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[6] Subhani M, Dhanda A, King JA, et al. “Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review.” eClinicalMedicine. 2024;78:102920. https://pubmed.ncbi.nlm.nih.gov/39764544/


Important: This content is for general education and is not medical advice. Talk with a licensed provider about your situation, including any concerns about alcohol use or interactions with your medication. If you are worried about your drinking, the SAMHSA National Helpline (1-800-662-4357) is free and confidential. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication. A licensed provider decides whether a prescription is appropriate. GLP-1 medications are not FDA-approved to treat alcohol use disorder. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound; they may differ in formulation, purity, and potency. Results vary. Trial results describe study participants and are not a prediction for any individual. Wegovy is a trademark of Novo Nordisk A/S. Zepbound is a trademark of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.

FAQ

Frequently Asked Questions

Everything you need to know about getting started.

Still have questions?

Contact our support team
Can I drink alcohol while on semaglutide or tirzepatide?
The FDA prescribing information for semaglutide and tirzepatide weight-loss medications does not list alcohol as a contraindication. However, GLP-1 medications slow gastric emptying, which may change how alcohol affects you, and the effect can be hard to predict. Alcohol can also make GLP-1 nausea worse. Moderation, and extra caution on days when your stomach side effects are worse, is a sensible starting point. Ask your prescriber what fits your situation, especially if you take insulin or a sulfonylurea.
Why do I not want to drink as much since starting semaglutide?
This is a real and increasingly studied effect. GLP-1 receptors are present in the brain's reward circuits, and GLP-1 medications appear to reduce the rewarding effects of alcohol in some people, similar to how they reduce food noise. Small early clinical trials are now testing this directly. Many people describe a reduction in alcohol desire that feels less like willpower and more like alcohol is simply less rewarding. If you are noticing this, it is worth discussing with your provider.
Does alcohol make GLP-1 side effects worse?
For many people, yes. Nausea is the most common GLP-1 side effect, particularly in the first weeks and after dose increases, and alcohol often worsens nausea. If you are already nauseous from the medication, drinking on top of it is likely to make it worse. Many people find their stomach side effects are strongest in the day or two after their weekly dose, which makes that a poor time to drink.

We're relaunching soon

We're relaunching as an independent GLP-1 guide. Leave your email and we'll let you know when your free custom report is ready.

Get Started

About This Site: Disclosures

Who We Are

transformationhealth.com is a website operated by Amerigo Health LLC. Transformation Health is an independent publisher. It does not provide medical care, prescribe, or sell medication, and does not give medical advice. Providers and programs mentioned on this site are independent third parties.

How We Make Money

Transformation Health does not accept payment from providers.

Educational Purpose

This content is for general education and is not medical advice. Talk with a licensed provider about your situation. Results vary. Trial results describe study participants and are not a prediction for any individual.

Compounded Medications

Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy, Ozempic, Zepbound, or Mounjaro. They may differ in formulation, purity, and potency.

Trademarks

Wegovy and Ozempic are trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are trademarks of Eli Lilly and Company. Transformation Health is not affiliated with or endorsed by these companies.